Inovio reported positive Phase 3 VGX-3100 data. In addition to treating cervical dysplasia, label expansion is likely. DNA plasmid technology is poised to create a broad array of commercial therapies.

The CRISPR technology market is segmented by product type into Cas9 And gRNA, design tool, plasmid and vector, and other delivery system products. The Cas9 And gRNA market was the largest segment ...

The company also has high hopes for its other asset, although it hasn’t yet made it into the clinic. Imunon is using preclinical trials to evaluate whether its multivalent DNA plasmid technology ...

The technology was first conceptualized at Colorado State University in 2018 and has since received support from CSU's Office of the Vice President for Research, the National Science Foundation ...

At the time, Charles River said the addressable market for Cognate’s CDMO services, primarily cell therapy and plasmid production, is approximately $1.5 billion and was expected to grow at least ...

For Research Use Only. Not for use in diagnostic procedures. The purification of plasmid DNA (pDNA) is essential in molecular biology research. Over the years, plasmid DNA isolation technology has ...

Inovio Pharmaceuticals, Inc. INO announced today the publication of a peer-reviewed paper demonstrating the success of its new DNA plasmid technology in generating therapeutic monoclonal antibodies.

DNA plasmid technology has many applications. Inovio’s Covid-19 vaccine may still have a global market. Inovio potential HPV related therapies look headed for success. Glioblastoma therapy ...

Cutting-edge centrifugation technology streamlines bacterial harvesting, DNA purification, and RNA synthesis for high-volume ...

Thursday, November 14th, 202411:00 AM - 12:30 PM ET Scientists use plasmids as the leading gene delivery technology for a variety of research and clinical applications related to gene therapy.

Recently published data demonstrated that plasmid-free technology could produce over tenfold more AAV compared with a transient approach and particles which are 5- to 60-fold more infectious ...